Difference between revisions of "Robledo-Cadena 2020 Pharmaceuticals (Basel)"
Line 2: | Line 2: | ||
|title=Robledo-Cadena DX, Gallardo-PĂ©rez JC, DĂĄvila-Borja V, Pacheco-VelĂĄzquez SC, Belmont-DĂaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-SĂĄnchez R, RodrĂguez-EnrĂquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 13:463. | |title=Robledo-Cadena DX, Gallardo-PĂ©rez JC, DĂĄvila-Borja V, Pacheco-VelĂĄzquez SC, Belmont-DĂaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-SĂĄnchez R, RodrĂguez-EnrĂquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 13:463. | ||
|info=[https://www.ncbi.nlm.nih.gov/pubmed/33333716 PMID: 33333716 Open Access] | |info=[https://www.ncbi.nlm.nih.gov/pubmed/33333716 PMID: 33333716 Open Access] | ||
|authors=Robledo-Cadena | |authors=Robledo-Cadena Diana Xochiquetzal, Gallardo-Perez Juan Carlos, Davila-Borja Victor, Pacheco-Velazquez Silvia Cecilia, Belmont-Diaz Javier Alejandro, Ralph Stephen John, Blanco-Carpintero Betsy Alejandra, Moreno-Ssnchez Rafael, Rodriguez-Enriquez Sara | ||
|year=2020 | |year=2020 | ||
|journal=Pharmaceuticals (Basel) | |journal=Pharmaceuticals (Basel) |
Revision as of 19:10, 22 January 2021
Robledo-Cadena DX, Gallardo-PĂ©rez JC, DĂĄvila-Borja V, Pacheco-VelĂĄzquez SC, Belmont-DĂaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-SĂĄnchez R, RodrĂguez-EnrĂquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 13:463. |
Robledo-Cadena Diana Xochiquetzal, Gallardo-Perez Juan Carlos, Davila-Borja Victor, Pacheco-Velazquez Silvia Cecilia, Belmont-Diaz Javier Alejandro, Ralph Stephen John, Blanco-Carpintero Betsy Alejandra, Moreno-Ssnchez Rafael, Rodriguez-Enriquez Sara (2020) Pharmaceuticals (Basel)
Abstract: This study shows that the non-steroidal anti-inflammatory drug (NSAID) celecoxib and its non-cyclooxygenase-2 (COX2) analogue dimethylcelecoxib (DMC) exert a potent inhibitory effect on the growth of human cervix HeLa multi-cellular tumor spheroids (MCTS) when added either at the beginning ("preventive protocol"; IC50 = 1 ± 0.3 nM for celecoxib and 10 ± 2 nM for DMC) or after spheroid formation ("curative protocol"; IC50 = 7.5 ± 2 ”M for celecoxib and 32 ± 10 ”M for DMC). These NSAID IC50 values were significantly lower than those attained in bidimensional HeLa cells (IC50 = 55 ± 9 ”M celecoxib and 48 ± 2 ”M DMC) and bidimensional non-cancer cell cultures (3T3 fibroblasts and MCF-10A mammary gland cells with IC50 from 69 to >100 ”M, after 24 h). The copper-based drug casiopeina II-gly showed similar potency against HeLa MCTS. Synergism analysis showed that celecoxib, DMC, and casiopeinaII-gly at sub-IC50 doses increased the potency of cisplatin, paclitaxel, and doxorubicin to hinder HeLa cell proliferation through a significant abolishment of oxidative phosphorylation in bidimensional cultures, with no apparent effect on non-cancer cells (therapeutic index >3.6). Similar results were attained with bidimensional human cervix cancer SiHa and human glioblastoma U373 cell cultures. In HeLa MCTS, celecoxib, DMC and casiopeina II-gly increased cisplatin toxicity by 41-85%. These observations indicated that celecoxib and DMC used as adjuvant therapy in combination with canonical anti-cancer drugs may provide more effective alternatives for cancer treatment. ⹠Keywords: Bliss-type additivism model, HeLa cells, Celecoxib, Dimethylcelecoxib, Drug synergism, Resistance index ⹠Bioblast editor: Plangger M
Labels: MiParea: Respiration
HRR: Oxygraph-2k
2021-01